Experimental immune drug now available for bone cancer patients
NCT ID NCT04571229
First seen Mar 25, 2026 · Last updated Apr 30, 2026 · Updated 5 times
Summary
This program provides access to an investigational drug called L-MTP-PE for people with osteosarcoma, a type of bone cancer. The drug works by activating white blood cells to help the immune system kill cancer cells. It is available to patients of any age who have had surgery to remove all visible tumors. This is not a cure, but a way to try to control the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OSTEOSARCOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-••••
Locations
-
Memorial Sloan Kettering Cancer Center (All Protocol Activities)
AVAILABLENew York, New York, 10065, United States
Contact Phone: •••-•••-••••
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.